By Connor Hart
AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.
The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial, which showed a 36% reduction in the risk of disease progression or death versus chemotherapy.
The approval extends to adult patients with unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer, the company said.
"This new approval brings this important medicine to an earlier treatment setting and a broader patient population with HER2-expressing metastatic breast cancer," said Dave Fredrickson, executive vice president of AstraZeneca's oncology hematology business unit.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
January 27, 2025 18:59 ET (23:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。